Jounce Therapeutics, Inc.
6 clinical trials · Sponsor
◉ Watch Jounce Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (NCT04669899) | Jounce Therapeutics, Inc. | 2021-01-12 |
| Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (NCT04549025) | Jounce Therapeutics, Inc. | 2020-10-19 |
| Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors (NCT04319224) | Jounce Therapeutics, Inc. | 2020-03-10 |
| Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (NCT03989362) | Jounce Therapeutics, Inc. | 2019-06-06 |
| Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies (NCT03790488) | Jounce Therapeutics, Inc. | 2018-12-06 |
Track Jounce Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.